Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Omni-Biotic Stress Release is a multi-strain probiotic dietary supplement designed to support the gut-brain axis and improve resilience during periods of stress. Developed by the Austrian company Omni-Biotic (Institut AllergoSan), it contains nine specific bacterial strains: *Lactobacillus casei* W56, *Lactococcus lactis* W19, *Lactobacillus acidophilus* W22, *Bifidobacterium lactis* W52, *Lactobacillus paracasei* W20, *Lactobacillus plantarum* W62, *Bifidobacterium lactis* W51, *Bifidobacterium bifidum* W23, and *Lactobacillus salivarius* W24. The formulation aims to strengthen the intestinal barrier, modulate the gut microbiome, and support the production of neurotransmitters such as serotonin and dopamine. Clinical evidence suggests it may improve mood, cognitive function, and memory, while reducing digestive symptoms associated with stress and irritable bowel syndrome (IBS). It is administered orally as a powder dissolved in water.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Omni-Biotic Stress Release.